Chemkart India Ltd. · BSE:CHEMKART
Chemkart India — Investor Presentation (September 2025)
33 slides from Chemkart India's investor presentation, Sep 11, 2025
Slide 1: BSE filing cover letter for investor presentation
CHEMKART INDIA LIMITED CIN-L51220MH2020PLC338631 403/404 K.L. Accolade, 4th Floor, Above Captain Gym, Nr. R.K. Hospital Santacruz (E), MUMBAI 400055 Email Id: [email protected] | Customer Care: +91 9136383828 11 Sept 2025 To, BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai - 400001 Securit
Slide 2: Chemkart India Ltd Investor Presentation - September 2025
Chemkart India Ltd Investor Presentation - September 2025
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Chemkart India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Company Overview, Industry Overview, Strategic Overview
Company Overview Industry Overview Strategic Overview Historical Financial Performance Investment Rationale
Slide 5: The Foundation of Our Future
The Foundation of Our Future Mission Vision To drive growth and To be a global leader in excellence in food and end-to-end CDMO health ingredients solutions and trusted through quality sourcing, distribution of food, trusted partnerships, and health, and specialty innovative, sustainable ingredients
Slide 6: Company Snapshot
Company Snapshot 10+ Product Categories Certifications: ISO 9001:2015 | FSSAI | ETC | 150+ Ingredients Pan-India Distribution Network Revenue: 32.7% 500+ Trusted Clients (3 Year CAGR) EBITDA: 67.1% PAT: 64.2% 46% 30K Sq.Ft Warehouse (FY25) ROE: ROCE: 49% Investor Presentation – August 2025 5
Slide 7: About Chemkart
About Chemkart Chemkart India Limited, established in March 2015 and headquartered in Mumbai, is a B2B supplier of high-quality raw ingredients used in the manufacturing of nutritional, sports, and health supplements. The company serves a broad spectrum of manufacturers across India, offering a dive
Slide 8: Path to Nutraceutical Leadership
Path to Nutraceutical Leadership New manufacturing unit to be completed and operational in • Launched Vinstar Biotech as FY27, driving mutifold growth a subsidiary to diversify and for the company broaden business horizons. • Established presence in SEZ with a dedicated sales unit to scale operation
Slide 9: Transitioning Into Manufacturing
Transtioning Into Manufacturing Chemkart India Limited (CIL) announced the commencement of full-scale construction of a greenfield facility at its wholly owned subsidiary, Easy Raw Materials Pvt. Ltd. (EZRM), located in the JNPT Special Economic Zone (SEZ), Maharashtra. This next-generation nutraceu
Slide 10: Leadership Behind Chemkart
Leadership Behind Chemkart Ankit Shailesh Mehta Parul Shailesh Mehta Shailesh Vinodrai Mehta Chairman & Managing Director Promoter & Executive Director Promoter & Executive Director He holds a Bachelor's degree in With 9 years of experience in the A commerce graduate from the (Chemical Engineering)
Slide 11: Showcasing Our Strength: Products & Partnerships
Showcasing Our Strength: Products & Partnerships Our Leading Product Portfolio Clientele at a Glance Glycine Creatine Monohydrate 200 Mesh Inositol BCAA 2:1:1 (Leucine, Isoleucine, Valine) L-Glutamine L-Carnitine N-Acetyl L-Cysteine (NAC) Taurine L-Glutathione (Reduced) Whey Protein Concentrate 80%
Slide 12: Domestic Stronghold with Emerging Global Reach
Domestic Stronghold with Emerging Global Reach Germany Slovakia Switzerland Turkey Portugal South Nepal Korea U.A.E Saudi Arabia Bhiwandi Geographic Revenue Breakup Sri Lanka 0.75% 99.25% New Zealand Export Domestic Warehousing facility in Bhiwandi, Maharashtra spans 28,259 sq. ft. across three floo
Slide 13: Robust Storage & Processing Capabilities
Robust Storage & Processing Capabilities 150+ Ingredients 30000 Sq.ft Warehouse 50+ 1.5MT/Day Blending Employee 1.8MT/Day Capacity Grinding Strength Capacity Investor Presentation – August 2025 12
Slide 14: Our Group Companies
Our Group Companies Vinstar Biotech Limited Easy Raw Materials Pvt. Ltd Supports science-led platforms in Focused on the manufacturing & biotech, life sciences, and chemicals. export of high-quality nutraceutical Its involvement aligns with and wellness products, driven by Chemkart’s vision of build
Slide 15: Certifications
Certifications ISO 9001:2015 Certified FSSAI License ISO 22000:2018 Certified HALAL Certified KOSHER Certified Investor Presentation – August 2025 14
Slide 16: Company Overview, Industry Overview, Strategic Overview
Company Overview Industry Overview Strategic Overview Historical Financial Performance Investment Rationale
Slide 17: Powering India's $76 Billion Health Revolution
Powering India’s $76 Billion Health Revolution India’s nutraceutical market is growing at 10% CAGR, projected to reach USD 76 billion by 2033, backed by rising health-conscious consumer spending. A wellness-focused middle class and expanding elderly population are driving sustained demand for functi
Slide 18: Trends Fueling the Next Wave of Nutraceutical Growth
Trends Fueling the Next Wave of Nutraceutical Growth India’s 1,700+ medicinal plants are fueling demand for standardized 01 herbs like turmeric, tulsi, and ashwagandha. Backed by modern AYURVEDA 2.0 extraction and global clinical validation, Ayurvedic blends are gaining popularity, with growing expo
Slide 19: Company Overview, Industry Overview, Strategic Overview
Company Overview Industry Overview Strategic Overview Historical Financial Performance Investment Rationale
Slide 20: Present Edge & Future Focus
Present Edge & Future Focus: Strategic Advantages Path Ahead Experienced Team: Product Expansion: Strong leadership with deep industry knowledge. Our new manufacturing facility marks strategic entry into CDMO, expanding capabilities and offerings. Cost-Efficient Operations: Vertical Integration: Lea
Slide 21: Driving Growth Through Strategic Outreach
Driving Growth Through Strategic Outreach Strengthening Digital B2B Presence By leveraging online B2B platforms, we’ve expanded nationwide visibility, generated high-quality leads, and strengthened our presence across chemical and nutraceutical industries. Customer-Centric Market Alignment Our sales
Slide 22: Company Overview, Industry Overview, Strategic Overview
Company Overview Industry Overview Strategic Overview Historical Financial Performance Investment Rationale
Slide 23: Segment-Wise Revenue Contribution
Segment-Wise Revenue Contribution FY24 FY25 1.7% 2.3% 2.7% 6.8% 24.9% 46.8% 33.2% 44.4% 2.7% 11.9% 3.0% 1.5% 3.2% 12.4% 0.9% 1.6% Amino Acids Health Supplement Herbal Extract Nucleotide Protein Sports Nutrition Vitamin Other Product Category FY24 FY25 Amino Acids 6176.68 9025.45 Health Supplement 16
Slide 24: Key Financial Highlights
Key Financial Highlights Revenue (INR Lacs) EBITDA (INR Lacs) and EBITDA Margin (%) PAT (INR Lacs) and PAT Margin (%) 2,426 20,328 3,276 13,138 13,203 2,091 1,452 766 1,105 15.80% 16.10% 11.90% 11.00% 8.40% 5.80% FY23 FY24 FY25 FY23 FY24 FY25 FY23 FY24 FY25 ROE (In %) ROCE (In %) 52.84% 51.24% 48.94
Slide 25: Consolidated Income Statement
Consolidated Income Statement Particulars (Rs. Lacs) FY24 FY25 Revenue from Operations 13,202.7 20,327.9 Cost of Materials Consumed 10.4 748.6 Purchase of Stock in Trade 10,701.6 17,123.4 Changes in Inventories in Stock in Trade -7.6 -1,469.5 Employee Expenses 115.2 212.6 Other Expenses 291.9 436.5
Slide 26: Standalone Income Statement
Standalone Income Statement Particulars (Rs. Lacs) FY24 FY25 Revenue from Operations 13,202.7 20,327.9 Cost of Materials Consumed 10.4 748.6 Purchase of Stock in Trade 10,580.5 17,123.4 Changes in Inventories in Stock in Trade -7.6 -1,469.5 Employee Expenses 80.7 214.7 Other Expenses 507.8 410.6 EBI
Slide 27: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (Rs. Lacs) Mar-24 Mar-25 EQUITY AND LIABILITIES (Rs. Lacs) Mar-24 Mar-25 Non ‐ Current Assets Shareholders Funds (a) Equity share capital 135.7 949.9 a)Property, plant and equipment and Intangible Assets (b)Reserves and Surplus 2,765.8 4,378.7 (c) Minority Inte
Slide 28: Standalone Balance Sheet
Standalone Balance Sheet Assets (Rs. Lacs) Mar-24 Mar-25 EQUITY AND LIABILITIES (Rs. Lacs) Mar-24 Mar-25 Non ‐ Current Assets Shareholders Funds (a) Equity share capital 135.7 949.9 a)Property, plant and equipment and Intangible Assets (b)Reserves and Surplus 2,739.6 4,400.9 (c) Minority Interest -
Slide 29: Consolidated Cashflow Statement
Consolidated Cashflow Statement Particulars (Rs. Lacs) Mar-24 Mar-25 Cash Flow from Operating Activities Profit before Tax 1,995.4 3,259.2 Adjustment for Non-Operating Items 149.6 199.7 Operating Profit before Working Capital Changes 2,145.0 3,458.9 Changes in Working Capital -1,650.0 -2,451.2 Cash
Slide 30: Standalone Cashflow Statement
Standalone Cashflow Statement Particulars (Rs. Lacs) Mar-24 Mar-25 Cash Flow from Operating Activities Profit before Tax 1,393.8 3,271.1 Adjustment for Non-Operating Items 717.2 215.9 Operating Profit before Working Capital Changes 2,110.9 3,487.0 Changes in Working Capital -1,544.9 -2,901.8 Cash Ge
Slide 31: Company Overview, Industry Overview, Strategic Overview
Company Overview Industry Overview Strategic Overview Historical Financial Performance Investment Rationale
Slide 32: Investment Rationale
Investment Rationale Profitable Product Mix Strong Customer Network Greenfield Expansion Specialty chemicals Focused on B2B, Investing in EZRM’s and nutraceuticals building trusted greenfield manufacturing across pharma, relationships to expand project to improve personal care, and B2B customers and
Slide 33: Thank You!
Company Chemkart India Limited CIN: U51220MH2020PLC338631 Email ID: [email protected] Tel: + 91 9136383828 Website: www.chemkart.com Thank You! Investor Relations Partner X-B4 Advisory LLP Rasika Sawant Tel: +91 95944 57518 Email ID: [email protected] Website: www.x-b4.com
Chemkart India — Investor Presentation (September 2025) on 6ix